Jefferies downgrades Accuray stock rating on guidance withdrawal By Investing.com

Jefferies downgraded Accuray to Hold from Buy and slashed its price target to $0.35 from $3.05, an 89% cut, after the company missed fiscal Q3 expectations and withdrew full-year guidance. Q3 EPS was -$0.09 versus -$0.02 expected, and revenue came in at $104.8 million versus $111.9 million consensus. Management cited Middle East geopolitical disruptions and China JV uncertainty as shipment and demand headwinds, reinforcing a more structural risk profile.

Analysis

This looks less like a one-quarter execution miss and more like a regime change in ARAY’s revenue durability. When a capital equipment vendor loses visibility in both EIMEA and China at the same time, the issue is usually not demand timing but deal conversion, installation cadence, and customer financing confidence — which can depress bookings for multiple quarters even if geopolitical headlines improve. The abrupt guidance withdrawal also forces the market to re-rate the name away from a simple recovery trade toward a balance-sheet and cash-burn story.

The second-order effect is that channel partners and hospitals will likely defer purchasing decisions until there is clarity on shipment timing and service support, which can create a self-reinforcing backlog problem. Competitively, larger radiation-therapy vendors with broader installed bases and stronger service revenue mix should take share, because buyers under uncertainty prefer suppliers that can guarantee delivery and provide predictable uptime economics. If ARAY’s product revenue is being delayed rather than simply pushed out, then the near-term risk is not just lower revenue but a weaker competitive position in the next budget cycle.

The selloff may still be incomplete if the market has not fully priced in covenant risk, working-capital pressure from delayed shipments, and the possibility that FY26 remains unguideable for more than one quarter. The key reversal catalyst would be evidence that bookings, not just shipments, are stabilizing — specifically, a return to credible order conversion in China or a resumption of EIMEA shipments within the next 60-90 days. Absent that, every quarter of delay increases the odds that estimates drift lower again and the equity becomes an optionality stub rather than a turnaround.

Consensus may be treating the geopolitical explanation as temporary, but the more important question is whether management can actually control end-market access and JV complexity. If not, the correct framing is not a wartime disruption but a structurally impaired growth algorithm. That means the stock could remain cheap for a long time while still being overvalued on a risk-adjusted basis.

Key Decisions for Investors

• Avoid initiating long exposure in ARAY for the next 1-2 quarters; the risk/reward is unfavorable until management proves bookings conversion and shipment normalization, with downside still open to a sub-$0.25 implied equity outcome if liquidity worsens.
• For short-oriented accounts, short ARAY on any relief rally back toward $0.40-$0.45 with a 4-8 week horizon; use the thesis that guidance reset typically takes multiple estimate cuts to fully clear the tape, offering roughly 2:1 downside/upside if the stock revisits prior lows.
• Pair trade: long a diversified med-tech capital equipment name with stable service annuity exposure, short ARAY, to isolate execution/geopolitics risk from sector beta; best held into the next earnings update when visibility should remain asymmetric.
• Use near-dated put options or put spreads on ARAY if available; the setup favors convex downside because the next catalyst is another update that can disappoint if shipments remain delayed.
• Set a reversal trigger only on evidence of order stabilization: if management restores guidance and confirms shipment resumption within 60-90 days, consider covering shorts immediately, as the equity could re-rate sharply off an extremely depressed base.